Cargando…

Insights into the molecular mechanisms of Huangqi decoction on liver fibrosis via computational systems pharmacology approaches

BACKGROUND: The traditional Chinese medicine Huangqi decoction (HQD) consists of Radix Astragali and Radix Glycyrrhizae in a ratio of 6: 1, which has been used for the treatment of liver fibrosis. In this study, we tried to elucidate its action of mechanism (MoA) via a combination of metabolomics da...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Biting, Wu, Zengrui, Li, Weihua, Liu, Guixia, Tang, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306236/
https://www.ncbi.nlm.nih.gov/pubmed/34301291
http://dx.doi.org/10.1186/s13020-021-00473-8
_version_ 1783727761684168704
author Wang, Biting
Wu, Zengrui
Li, Weihua
Liu, Guixia
Tang, Yun
author_facet Wang, Biting
Wu, Zengrui
Li, Weihua
Liu, Guixia
Tang, Yun
author_sort Wang, Biting
collection PubMed
description BACKGROUND: The traditional Chinese medicine Huangqi decoction (HQD) consists of Radix Astragali and Radix Glycyrrhizae in a ratio of 6: 1, which has been used for the treatment of liver fibrosis. In this study, we tried to elucidate its action of mechanism (MoA) via a combination of metabolomics data, network pharmacology and molecular docking methods. METHODS: Firstly, we collected prototype components and metabolic products after administration of HQD from a publication. With known and predicted targets, compound-target interactions were obtained. Then, the global compound-liver fibrosis target bipartite network and the HQD-liver fibrosis protein–protein interaction network were constructed, separately. KEGG pathway analysis was applied to further understand the mechanisms related to the target proteins of HQD. Additionally, molecular docking simulation was performed to determine the binding efficiency of compounds with targets. Finally, considering the concentrations of prototype compounds and metabolites of HQD, the critical compound-liver fibrosis target bipartite network was constructed. RESULTS: 68 compounds including 17 prototype components and 51 metabolic products were collected. 540 compound-target interactions were obtained between the 68 compounds and 95 targets. Combining network analysis, molecular docking and concentration of compounds, our final results demonstrated that eight compounds (three prototype compounds and five metabolites) and eight targets (CDK1, MMP9, PPARD, PPARG, PTGS2, SERPINE1, TP53, and HIF1A) might contribute to the effects of HQD on liver fibrosis. These interactions would maintain the balance of ECM, reduce liver damage, inhibit hepatocyte apoptosis, and alleviate liver inflammation through five signaling pathways including p53, PPAR, HIF-1, IL-17, and TNF signaling pathway. CONCLUSIONS: This study provides a new way to understand the MoA of HQD on liver fibrosis by considering the concentrations of components and metabolites, which might be a model for investigation of MoA of other Chinese herbs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-021-00473-8.
format Online
Article
Text
id pubmed-8306236
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-83062362021-07-28 Insights into the molecular mechanisms of Huangqi decoction on liver fibrosis via computational systems pharmacology approaches Wang, Biting Wu, Zengrui Li, Weihua Liu, Guixia Tang, Yun Chin Med Research BACKGROUND: The traditional Chinese medicine Huangqi decoction (HQD) consists of Radix Astragali and Radix Glycyrrhizae in a ratio of 6: 1, which has been used for the treatment of liver fibrosis. In this study, we tried to elucidate its action of mechanism (MoA) via a combination of metabolomics data, network pharmacology and molecular docking methods. METHODS: Firstly, we collected prototype components and metabolic products after administration of HQD from a publication. With known and predicted targets, compound-target interactions were obtained. Then, the global compound-liver fibrosis target bipartite network and the HQD-liver fibrosis protein–protein interaction network were constructed, separately. KEGG pathway analysis was applied to further understand the mechanisms related to the target proteins of HQD. Additionally, molecular docking simulation was performed to determine the binding efficiency of compounds with targets. Finally, considering the concentrations of prototype compounds and metabolites of HQD, the critical compound-liver fibrosis target bipartite network was constructed. RESULTS: 68 compounds including 17 prototype components and 51 metabolic products were collected. 540 compound-target interactions were obtained between the 68 compounds and 95 targets. Combining network analysis, molecular docking and concentration of compounds, our final results demonstrated that eight compounds (three prototype compounds and five metabolites) and eight targets (CDK1, MMP9, PPARD, PPARG, PTGS2, SERPINE1, TP53, and HIF1A) might contribute to the effects of HQD on liver fibrosis. These interactions would maintain the balance of ECM, reduce liver damage, inhibit hepatocyte apoptosis, and alleviate liver inflammation through five signaling pathways including p53, PPAR, HIF-1, IL-17, and TNF signaling pathway. CONCLUSIONS: This study provides a new way to understand the MoA of HQD on liver fibrosis by considering the concentrations of components and metabolites, which might be a model for investigation of MoA of other Chinese herbs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13020-021-00473-8. BioMed Central 2021-07-23 /pmc/articles/PMC8306236/ /pubmed/34301291 http://dx.doi.org/10.1186/s13020-021-00473-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wang, Biting
Wu, Zengrui
Li, Weihua
Liu, Guixia
Tang, Yun
Insights into the molecular mechanisms of Huangqi decoction on liver fibrosis via computational systems pharmacology approaches
title Insights into the molecular mechanisms of Huangqi decoction on liver fibrosis via computational systems pharmacology approaches
title_full Insights into the molecular mechanisms of Huangqi decoction on liver fibrosis via computational systems pharmacology approaches
title_fullStr Insights into the molecular mechanisms of Huangqi decoction on liver fibrosis via computational systems pharmacology approaches
title_full_unstemmed Insights into the molecular mechanisms of Huangqi decoction on liver fibrosis via computational systems pharmacology approaches
title_short Insights into the molecular mechanisms of Huangqi decoction on liver fibrosis via computational systems pharmacology approaches
title_sort insights into the molecular mechanisms of huangqi decoction on liver fibrosis via computational systems pharmacology approaches
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306236/
https://www.ncbi.nlm.nih.gov/pubmed/34301291
http://dx.doi.org/10.1186/s13020-021-00473-8
work_keys_str_mv AT wangbiting insightsintothemolecularmechanismsofhuangqidecoctiononliverfibrosisviacomputationalsystemspharmacologyapproaches
AT wuzengrui insightsintothemolecularmechanismsofhuangqidecoctiononliverfibrosisviacomputationalsystemspharmacologyapproaches
AT liweihua insightsintothemolecularmechanismsofhuangqidecoctiononliverfibrosisviacomputationalsystemspharmacologyapproaches
AT liuguixia insightsintothemolecularmechanismsofhuangqidecoctiononliverfibrosisviacomputationalsystemspharmacologyapproaches
AT tangyun insightsintothemolecularmechanismsofhuangqidecoctiononliverfibrosisviacomputationalsystemspharmacologyapproaches